News | Contrast Media | July 18, 2017

Company will gradually discontinue Hexabrix and Optimark, which are indicated for X-ray and MRI, respectively, and are similar to other existing agents in the company’s product line

Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast

July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and sodium ioxaglate) and Optimark (gadoversetamide).

Following the acquisition of Mallinckrodt’s contrast media & delivery systems business, Guerbet has taken measures to streamline its brand portfolio.

In 2015, it announced the withdrawal in the United States of Hexabrix, an iodinated contrast medium for X-ray imaging that has the same indications as two other Guerbet products, Optiray (ioversol) and Xenetix (iobitridol). Hexabrix sales in Europe, Asia and Latin America will progressively cease, by the end of 2019 at the latest. Optiray and Xenetix cover more than 70 countries.

Guerbet’s decision to phase out Optimark is similar: Optimark and Dotarem (gadoteric acid) are both gadolinium-based contrast agents and have similar indications for magnetic resonance imaging (MRI). Optimark is a linear agent and faces decreasing worldwide demand, while Dotarem, a macrocyclic and ionic agent, has seen worldwide demand increase, according to the company. Dotarem is registered in more than 70 countries.

Sales of Optimark will end July 26, 2017 in European Union countries. Then, and in order to ensure a smooth transition and continuous supply for patients, Optimark phase-out will be progressively implemented in other geographic areas until the end of 2019.

This move to streamline its gadolinium-based contrast agent portfolio through a focus on Dotarem is consistent with recent recommendations of the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency.

Read the article "Recent Developments and Issues in Contrast Media."

For more information: www.guerbet.com


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

October 17, 2023 — Halo Precision Diagnostics, a leader in early disease detection using precision diagnostics, today ...

Time October 17, 2023
arrow
News | Ultrasound Imaging

September 15, 2023 — Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to ...

Time September 15, 2023
arrow
News | Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 28, 2023
arrow
Subscribe Now